ArticleClinical and experimental medicine2025
CD2AP is a disulfidptosis modulator and prognostic biomarker in hepatocellular carcinoma.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Disulfidptosis: Mechanisms, evidence boundaries, and translational opportunities.Redox biology · 2026Review
- Integrated Transcriptomic Analyses Identify Four Prognosis-Associated Genes in Hepatocellular Carcinoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
CD2-associated protein (CD2AP) is an adapter protein that stabilizes the actin cytoskeleton and is closely linked to disulfidptosis. However, its functional role in hepatocellular carcinoma (HCC) progression and disulfidptosis remains undefined. Herein, pan-cancer multiomics analyses were performed on 33 malignancies from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) cohorts to evaluate CD2AP expression patterns, prognostic significance, and interactions with the tumor immune microenvironment. Clinical validation was performed using 70 HCC specimens, with qRT-PCR analysis and survival assessments. CD2AP expression was significantly elevated in tumor tissues across multiple cancer types and correlated with poor survival outcomes. In tumor tissues, high CD2AP expression positively correlated with the expression of immune checkpoints, including HAVCR2, CTLA4, CD274, TIGIT, and PDCD1. Additionally, qRT-PCR analysis of 70 HCC patients in our cohort confirmed a marked upregulation of CD2AP in HCC tumor tissues. Specifically, Kaplan-Meier analysis further revealed that high CD2AP expression was associated with reduced overall survival and recurrence-free survival in our HCC cohort. Functional experiments demonstrated that CD2AP silencing inhibited HCC cell proliferation and enhanced disulfidptosis susceptibility in SLC7A11-high cells, likely via NADPH depletion and actin network disruption. In conclusion, our findings indicate that CD2AP functions as an oncogene in HCC, promoting tumor progression by regulating disulfidptosis. This study provides novel insights into CD2AP as a potential prognostic biomarker and therapeutic target for HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.